LCH-IV : International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

Two/ThreePhase Two/Three

0-18Age 0-18

Blood<br/>CancersCancer LocationBlood
Cancers

Systemic therapy | Blood / Myeloma / LymphomaLangerhans Cell Histiocytosis

Trial Overview Read MoreRead more

This phase II/III trial is looking at different treatment protocols for children and adolescents with Langerhans Cell Histiocytosis.
 

This trial is treating patients with Langerhans Cell Histiocytosis.

This is a systemic therapy trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis

Other Non-Commercial Sponsor

Dana-Farber Cancer Institute

Summary

The LCH-IV is an international, multicenter, prospective clinical study for pediatric Langerhans Cell Histiocytosis LCH (age < 18="">

Recruiting Hospitals Read MoreRead more

Monash Children's Cancer Centre
Clayton
Ms Irina Arzhintar
Irina.Arzhintar@monashhealth.org
(03) 8572 3490

Royal Childrens Hospital
Parkville
Trial Coordinator
CCC.ClinicalTrials@rch.org.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next